Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
ANRO Stock Chart & Stats
$20.11
-$0.09(-1.99%)
At close: 4:00 PM EST
$20.11
-$0.09(-1.99%)
Day’s Range― - ―
52-Week Range$1.60 - $21.56
Previous CloseN/A
Volume104.17K
Average Volume (3M)2.30M
Market Cap
$624.74M
Enterprise Value$556.70M
Total Cash (Recent Filing)$137.82M
Total Debt (Recent Filing)$27.52M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding31,066,336
10 Day Avg. Volume557,199
30 Day Avg. Volume2,303,174
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.69
Price to Sales (P/S)0.00
P/FCF Ratio-2.10
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-920.17
Enterprise Value/Ebitda-9.37
Forecast
1Y Price Target
$36.00Price Target Upside79.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentThe acceleration of ALTO-207 development, supported by a $50M private placement, indicates strong pipeline progress, potentially leading to significant market opportunities in the treatment of depression.
Regulatory ProgressThe fast track designation for ALTO-101 enhances the company's ability to expedite the development and review process, potentially bringing innovative treatments to market faster and improving competitive positioning.
Innovative Biomarker StrategyUtilizing innovative biomarkers like theta ITC for CIAS offers a differentiated approach in clinical trials, potentially improving treatment efficacy and patient outcomes, enhancing long-term competitive advantage.
Bears Say
Cash BurnThe high cash burn rate reflects significant operational expenses without revenue offset, posing a risk to financial sustainability and increasing dependency on external funding.
Rising Debt LevelsIncreasing debt levels can strain financial resources, limiting flexibility and potentially impacting the company's ability to invest in long-term growth initiatives.
Widening LossesWidening losses indicate a rising cost base without revenue generation, highlighting financial instability and the challenge of achieving profitability in the near term.
Alto Neuroscience, Inc. News
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $1.60 and its highest was $21.56 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $624.74M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is May 20, 2026 which is in 76 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Oct 31, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.668 by $0.148.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 31,066,336 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.668. Following the earnings report the stock price went down -0.908%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alto Neuroscience, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.00 (79.02% Upside)
$36.00 (79.02% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.39%
12-Months-Change
Fundamentals
Return on Equity
-45.01%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
ANRO Stock 12 Month Forecast
Average Price Target
$36.00
▲(79.02% Upside)
Technical Analysis
Cassava Sciences
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Ownership Overview
8.00% Insiders
5.45% Mutual Funds
1.32% Other Institutional Investors
80.33% Public Companies and
Individual Investors